This company has been marked as potentially delisted and may not be actively trading. Bellerophon Therapeutics (BLPH) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock BLPH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Bellerophon Therapeutics Inc. (BLPH) ChartsDecember 23, 2024 | nasdaq.comAdocia SA (A89.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBellerophon Therapeutics, Inc. (BLPH)February 25, 2024 | uk.finance.yahoo.comBellerophon Therapeutics Inc (BLPH)February 15, 2024 | investing.comBellerophon Offers Series A Stock in Private SaleJanuary 31, 2024 | msn.comHilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company BellerophonNovember 28, 2023 | benzinga.comBellerophon Therapeutics Inc BLPHNovember 2, 2023 | morningstar.comMBLPH - Bellerophon Therapeutics, Inc.August 8, 2023 | finance.yahoo.comWhat's Happening With Bellerophon Therapeutics Stock Today?July 25, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?July 25, 2023 | investorplace.comBellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04July 6, 2023 | msn.comThe Latest Analyst Ratings for Bellerophon TherapeuticsJune 6, 2023 | markets.businessinsider.comIs Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?June 6, 2023 | finance.yahoo.comLaidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)June 6, 2023 | msn.comHC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy RecommendationJune 6, 2023 | msn.comBellerophon Therapeutics Stock Nosedive: Here's WhyJune 5, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?June 5, 2023 | msn.comBellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseJune 5, 2023 | finance.yahoo.comBellerophon Therapeutics (Nasdaq:BLPH) HeadlineTrading was temporarily halted for "BLPH" at 06:06 AM with a stated reason of "News pending."...June 5, 2023 | marketbeat.comLucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losersMay 19, 2023 | msn.comHC Wainwright Brokers Increase Earnings Estimates for Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)May 19, 2023 | marketbeat.comBellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week aloneMay 17, 2023 | finance.yahoo.comBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 16, 2023 | finanznachrichten.deBellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseMay 11, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should KnowApril 28, 2023 | finance.yahoo.comBellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?April 24, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should KnowApril 19, 2023 | finance.yahoo.comBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Short Interest Down 40.8% in MarchApril 16, 2023 | marketbeat.comBellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should KnowApril 13, 2023 | msn.comHC Wainwright & Co. Reiterates Bellerophon Therapeutics (BLPH) Buy RecommendationApril 4, 2023 | msn.comH.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH)April 4, 2023 | markets.businessinsider.comWhen Will Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Turn A Profit?April 3, 2023 | finance.yahoo.comBellerophon Therapeutics GAAP EPS of -$2.08 misses by $0.06April 2, 2023 | seekingalpha.comBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial ResultsMarch 31, 2023 | finanznachrichten.deBellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial ResultsMarch 31, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's WhyMarch 28, 2023 | finance.yahoo.comHere's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep goingMarch 10, 2023 | finance.yahoo.comBellerophon to Buy Rival Firm’s SharesMarch 6, 2023 | baystreet.caBellerophon Therapeutics Surges 30% On Share Subscription Agreement With An Institutional InvestorMarch 6, 2023 | markets.businessinsider.comBellerophon Therapeutics Announces $5 Million Registered Direct OfferingMarch 6, 2023 | finance.yahoo.comBellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung DiseaseFebruary 9, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseJanuary 18, 2023 | finance.yahoo.comHow Is The Market Feeling About Bellerophon Therapeutics?January 6, 2023 | benzinga.comShort Volatility Alert: Bellerophon TherapeuticsJanuary 6, 2023 | benzinga.comCompanies Like Bellerophon Therapeutics (NASDAQ:BLPH) Could Be Quite RiskyJanuary 6, 2023 | finance.yahoo.comBellerophon Therapeutics Shares Gained Over 200% TodayJanuary 5, 2023 | finance.yahoo.comBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finanznachrichten.deBellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comBellerophon (BLPH) Receives FDA Acceptance to Reduce Study SizeSeptember 28, 2022 | finance.yahoo.com Get Bellerophon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLPH Media Mentions By Week BLPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLPH News Sentiment▼0.000.72▲Average Medical News Sentiment BLPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLPH Articles This Week▼00▲BLPH Articles Average Week Get the Latest News and Ratings for BLPH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Bellerophon Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Bon Natural Life News Trevena News Vincerx Pharma News NuCana News Syros Pharmaceuticals News Smart for Life News Virpax Pharmaceuticals News Ainos News BriaCell Therapeutics News Novartis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLPH) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLPH Stock Alerts